ArticleFrontiers in public health2026
A time-delayed epidemic model for control of highly pathogenic avian influenza (HPAI H5Nx) with vaccination, compliance, and non-pharmaceutical interventions.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Highly pathogenic avian influenza poses an ongoing zoonotic risk with the potential for severe human outbreaks. Existing epidemic models often assume immediate vaccine effectiveness and homogeneous populations, which may overestimate the impact of vaccination during the early phase of an outbreak. This study develops a time-delayed epidemic model to examine how vaccination timing, delayed immune protection, behavioral heterogeneity, and non-pharmaceutical interventions jointly shape the transmission dynamics of a hypothetical human outbreak of highly pathogenic avian influenza H5Nx. Methods: A time-delayed epidemic model was developed that incorporates incubation delay, vaccine deployment delay, and vaccine-to-protection delay. The population was stratified into vaccine-accepting and vaccine-hesitant groups to represent behavioral heterogeneity in vaccine uptake. The model was analyzed through reproduction number and stability analyses, and numerical simulations were performed to evaluate the effects of delays on peak infectious burden, cumulative infections, epidemic timing, and intervention effectiveness. Results: The results showed that delays in vaccine deployment and immune protection substantially reduced the effectiveness of vaccination in limiting peak infection burden. Earlier vaccine deployment reduced transmission during the initial growth phase, whereas delayed deployment shifted the impact of vaccination to later stages of the epidemic. Higher vaccination acceptance reduced both peak burden and cumulative infections, while vaccine-hesitant individuals consistently experienced higher attack rates. Non-pharmaceutical interventions reduced transmission immediately and exerted the strongest influence during the early phase of the epidemic. The incubation delay altered epidemic timing and transient dynamics without changing the invasion threshold. Discussion: The findings demonstrate that epidemic outcomes depend strongly on intervention timing, the rate at which immune protection develops, and population behavior. Delays associated with vaccine availability and immune response can substantially diminish the short-term benefits of vaccination, particularly when outbreak growth is rapid. Incorporating behavioral heterogeneity and multiple delay mechanisms provides a more realistic basis for evaluating intervention strategies and strengthening preparedness for future human outbreaks of highly pathogenic avian influenza.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.